Tectonic Therapeutic, Inc.
Financials
Valuation Metrics
Tectonic Therapeutic, Inc.'s Market Cap is $528M. At end of 2025 it was $382M. Ranked #2773 of 3,121 in US market (top 89%), #1209 of 1,463 on NASDAQ (top 83%), #224 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 84%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $528M | US#2,773/3,121 Sec#224/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-86M | US—/3,121 Sec—/266 |
| Total Assets | $237M | US#2,968/3,121 Sec#237/266 |
| Net Assets | $224M | US#2,645/3,121 Sec#179/266 |
| Employees | 60 | US#2,697/3,121 Sec#204/266 |
| Value | ||
| P/B | 2.36x | US#1,472/3,121 Sec#64/266 |
| FCF Yield | -13.73% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -38.32% | US#2,617/3,121 Sec#131/266 |
| ROA | -36.19% | US#2,925/3,121 Sec#176/266 |
| Financial Health | ||
| Debt Ratio | 5.89% | US#49/3,121 Sec#21/266 |
| Total Debt | $4M | US#2,918/3,121 Sec#221/266 |
| FCF | $-72M | US#2,580/3,121 Sec#127/266 |
| Cash | $227M | US#1,634/3,121 Sec#97/266 |
| Current Ratio | 22.29x | US#105/3,121 Sec#18/266 |
| Performance | ||
| 1Y Return | 72.63% | US#294/3,121 Sec#77/266 |
| 1M Return | -27.11% | US#3,053/3,121 Sec#256/266 |
| From 52W High | -31.70% | US#2,119/3,121 Sec#167/266 |
| 1Y MDD | -28.82% | US#1,295/3,121 Sec#82/266 |
| Trading | ||
| Volume | 286,807 shares | US#2,709/3,121 Sec#253/266 |
| Trading Value | $8M | US#2,678/3,121 Sec#224/266 |
| Per Share | ||
| EPS | $-4.39 | US—/3,121 Sec—/266 |
| BPS | $11.45 | US#1,754/3,121 Sec#65/266 |
Company Info
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.